Betamek partners SiGenex for genomics diagnostics development


From left: Ahmad Subri Abdullah, chairman of Betamek; Azrul Reza Aziz, CEO of MARii; and Tanvir Rasab, CEO of SiGenex

KUALA LUMPUR: Betamek Bhd via its wholly-owned subsidiary Betamek Research Sdn Bhd has inked a memorandum of collaboration with Singapore-based SiGenex Global Holdings Pte Ltd for the development of a more cost-effective next-generation AI-integrated genomics diagnostic and sequencing solution.

Under the partnership, Betamek Research will leverage its engineering and electronics manufacturing expertise to support the design-for-manufacturing (DFM) and assembly of SiGenex’s proprietary Benchtop Integrated Next Generation Sequencing (NGS) platform.

According to the a statement issued by Betamek, the NGS platform utilises cutting-edge Digital Microfluidics (DMF) technology for cost-effective, high-precision DNA/RNA sequencing.

The collaboration encompasses the development of manufacturing protocols, establishment of ISO and GMP-compliant facilities, and provision of end-to-end engineering and R&D support for scale-up.

Once successfully validated, SiGenex intends to exclusively outsource the manufacturing and assembly of its NGS platforms and cartridges to Betamek for the Asia region.

"This collaboration marks an important diversification milestone for Betamek as we apply our EMS and R&D capabilities beyond automotive electronics into the high-value biotech sector.

"SiGenex’s breakthrough NGS platform aligns with our strategic vision to become a regional centre for precision manufacturing and smart diagnostics assembly. We are confident this partnership will open up new innovation and commercial opportunities across the region," said Betamek executive director Muhammad Fauzi Abd Ghani.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Betamek , SiGenex , genomics , diagnostics

Next In Business News

Mulling Malaysia’s shared ownership
Parked above, stuck below
The limitations of TEDUH
India’s overseas investment rush
A construction boom with an expiry date?
Moderna’s co-founder bets on long shots
A banker fuelling fintech’s rise
Battle for UK deposits
Hospital mergers can�raise competition challenges
WHERE SANCTUARY MEETS SUSTAINABILITY

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read